A comprehensive study of SARS-CoV-2 main protease (M

Antimicrobial resistance Omicron SARS-CoV-2 ensitrelvir nirmatrelvir non-gain-of-function research protease inhibitor resistance mutations selection pressure experiments

Journal

bioRxiv : the preprint server for biology
Titre abrégé: bioRxiv
Pays: United States
ID NLM: 101680187

Informations de publication

Date de publication:
04 Oct 2023
Historique:
pubmed: 9 10 2023
medline: 9 10 2023
entrez: 9 10 2023
Statut: epublish

Résumé

Nirmatrelvir was the first protease inhibitor (PI) specifically developed against the SARS-CoV-2 main protease (3CL

Identifiants

DOI: 10.1101/2023.09.22.558628 PMID: 37808638 PMC: PMC10557589
pubmed: 37808638
doi: 10.1101/2023.09.22.558628
pmc: PMC10557589
pii:
doi:

Types de publication

Preprint

Langues

eng

Subventions

Organisme : NIAID NIH HHS
ID : U19 AI171954
Pays : United States

Déclaration de conflit d'intérêts

D.v.L. is founder of ViraTherapeutics GmbH. D.v.L serves as a scientific advisor to Boehringer Ingelheim and Pharma KG. E.H. and D.v.L have received an Austrian Science Fund (FWF) grant in the special call “SARS urgent funding”. E.H. is a registered consultant at Guidepoint. D. Bante holds stocks of Pfizer Inc. and Oxford Nanopore Technologies plc. S.A.M and R.S.H. are inventors on the patent application “Live cell assay for protease inhibition”, application number WO/2022/094463. All other authors declare they have no competing interests.

Auteurs

Francesco Costacurta (F)

Institute of Virology, Medical University of Innsbruck, Innsbruck, 6020, Tyrol, Austria.

Andrea Dodaro (A)

Molecular Modeling Section (MMS), Department of Pharmaceutical and Pharmacological Sciences, University of Padua, Via F. Marzolo 5, 35131, Padova, Italy.

David Bante (D)

Institute of Virology, Medical University of Innsbruck, Innsbruck, 6020, Tyrol, Austria.

Helge Schöppe (H)

Institute of Pharmacy/Pharmaceutical Chemistry, University of Innsbruck, Innsbruck, 6020, Tyrol, Austria.

Bernhard Sprenger (B)

Department of Biochemistry, University of Innsbruck, Innsbruck, 6020, Austria.

Seyed Arad Moghadasi (SA)

Department of Biochemistry, Molecular Biology and Biophysics, Institute for Molecular Virology, University of Minnesota, Minneapolis, MN 55455, United States.

Jakob Fleischmann (J)

Institute of Molecular Biology, University of Innsbruck, Innsbruck, 6020, Tyrol, Austria.
Tyrolean Cancer Research Institute (TKFI), Innrain 66, Innsbruck, 6020, Tyrol, Austria.

Matteo Pavan (M)

Molecular Modeling Section (MMS), Department of Pharmaceutical and Pharmacological Sciences, University of Padua, Via F. Marzolo 5, 35131, Padova, Italy.

Davide Bassani (D)

Molecular Modeling Section (MMS), Department of Pharmaceutical and Pharmacological Sciences, University of Padua, Via F. Marzolo 5, 35131, Padova, Italy.

Silvia Menin (S)

Molecular Modeling Section (MMS), Department of Pharmaceutical and Pharmacological Sciences, University of Padua, Via F. Marzolo 5, 35131, Padova, Italy.

Stefanie Rauch (S)

Institute of Virology, Medical University of Innsbruck, Innsbruck, 6020, Tyrol, Austria.

Laura Krismer (L)

Institute of Virology, Medical University of Innsbruck, Innsbruck, 6020, Tyrol, Austria.

Anna Sauerwein (A)

Institute of Virology, Medical University of Innsbruck, Innsbruck, 6020, Tyrol, Austria.

Anne Heberle (A)

Institute of Virology, Medical University of Innsbruck, Innsbruck, 6020, Tyrol, Austria.

Toni Rabensteiner (T)

Institute of Virology, Medical University of Innsbruck, Innsbruck, 6020, Tyrol, Austria.

Joses Ho (J)

Bioinformatics Institute, Agency for Science Technology and Research, Singapore.

Reuben S Harris (RS)

Department of Biochemistry and Structural Biology, University of Texas Health San Antonio, San Antonio, TX 78229, United States.
Howard Hughes Medical Institute, University of Texas Health San Antonio, San Antonio, TX 78229, United States.

Eduard Stefan (E)

Institute of Molecular Biology, University of Innsbruck, Innsbruck, 6020, Tyrol, Austria.
Tyrolean Cancer Research Institute (TKFI), Innrain 66, Innsbruck, 6020, Tyrol, Austria.

Rainer Schneider (R)

Department of Biochemistry, University of Innsbruck, Innsbruck, 6020, Austria.

Teresa Kaserer (T)

Institute of Pharmacy/Pharmaceutical Chemistry, University of Innsbruck, Innsbruck, 6020, Tyrol, Austria.

Stefano Moro (S)

Molecular Modeling Section (MMS), Department of Pharmaceutical and Pharmacological Sciences, University of Padua, Via F. Marzolo 5, 35131, Padova, Italy.

Dorothee von Laer (D)

Institute of Virology, Medical University of Innsbruck, Innsbruck, 6020, Tyrol, Austria.

Emmanuel Heilmann (E)

Institute of Virology, Medical University of Innsbruck, Innsbruck, 6020, Tyrol, Austria.

Classifications MeSH